ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Provided By GlobeNewswire
Last update: Oct 30, 2024
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement
Read more at globenewswire.comNASDAQ:PMN (2/21/2025, 8:00:01 PM)
0.815
-0.09 (-9.45%)
Find more stocks in the Stock Screener
